Latest news with #JeffreyP.Campisi
Associated Press
15-05-2025
- Business
- Associated Press
Kaplan Fox is Investigating Potential Securities Law Violations Against Iovance Biotherapeutics, Inc. (IOVA)
NEW YORK, NY - May 15, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Iovance Biotherapeutics, Inc. ('Iovance' or the 'Company') (NASDAQ: IOVA). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an Iovance investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571. On May 8, 2025, after the markets closed, Iovance announced its first quarter 2025 financial results. The Company revealed that total product revenue for the quarter was $49.3 million, a decline from the prior quarter's reported revenue of $73.7 million. The Company also disclosed that full fiscal year 2025 revenue guidance was being revised to $250 million to $300 million from previous guidance of $450 million to $475 million. Iovance stated that it was 'revising full-year 2025 revenue guidance to reflect recent launch dynamics' of the Company's T cell immunotherapy, Amtagvi (lifileucel). Amtagvi was approved by the U.S. Food and Drug Administration in February 2024 and was commercially launched in the first half of 2024. Following this news, the price of Iovance stock fell $1.42 per share, nearly 45%, to close at $1.75 per share on May 9, 2025. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: CONTACT: Jeffrey P. Campisi KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (212) 329-8571 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Associated Press
22-04-2025
- Business
- Associated Press
Kaplan Fox Alerts Zynex, Inc. (ZYXI) Investors to a Securities Class Action Lawsuit - Deadline is May 19, 2025
NEW YORK - April 21, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Zynex, Inc. ('Zynex' or the 'Company') (NASDAQ: ZYXI) on behalf of investors that purchased or otherwise acquired Zynex securities between March 13, 2023 and March 11, 2025 (the 'Class Period'). CLICK HERE TO JOIN THE CASE If you are an investor in Zynex and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than May 19, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. According to the complaint, on March 11, 2025, after the markets closed, Zynex reported their fourth quarter and full year financial results. The Company revealed a significant revenue 'shortfall' in the quarter 'due to slower than normal payments from certain payers.' The Company also revealed that Tricare, a health insurance program for the U.S. Military, 'has temporarily suspended payments as they review prior claims.' Following this news, the price of Zynex stock fell $3.59 per share, over 51%, to close at $3.41 per share on March 12, 2025. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (1) Zynex shipped products, including electrodes, in excess of need; (2) as a result of this practice, the Company inflated its revenue; (3) Zynex's practice of filing false claims drew scrutiny from insurers, including Tricare; and (4) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT: Jeffrey P. Campisi KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (212) 329-8571 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Associated Press
08-04-2025
- Business
- Associated Press
Kaplan Fox & Kilsheimer LLP is Investigating Aldeyra Therapeutics, Inc. (ALDX) for Potential Securities Law Violations
NEW YORK, NY - April 8, 2025 ( NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Aldeyra Therapeutics, Inc. ('Aldeyra Therapeutics' or the 'Company') (NASDAQ: ADLX). If you are an Aldeyra Therapeutics investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571. On April 3, 2025, before the market opened, Aldeyra Therapeutics disclosed that the FDA issued a second Complete Response Letter ('CRL') for reproxalap, its lead dry eye disease drug candidate. According to the Company, the CRL stated that the NDA 'failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes' and that the Company should conduct 'at least one additional adequate and well-controlled study to demonstrate a positive effect on the treatment for ocular symptoms of a dry eye.' The Company further stated that the CRL 'identified concerns with the data from the trial submitted to the NDA that may have affected interpretation of the results, which the FDA stated may be related to methodological issues, including a difference in baseline scores across treatments arms.' Todd C. Brady, the President and Chief Executive Officer of the Company stated that '[p]ending positive results from the ongoing clinical trials and discussions with the FDA, we look forward to a potential NDA resubmission mid-year 2025.' Following this news, the price of Aldeyra Therapeutics stock fell $3.91 per share, or over 73%, to close at $1.42 per share on heavier than average trading volume. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Jeffrey P. Campisi KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (212) 329-8571 Laurence D. King 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Associated Press
28-03-2025
- Business
- Associated Press
ZYNEX DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on May 19, 2025
NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Zynex, Inc. ('Zynex' or the 'Company') (NASDAQ: ZYXI) on behalf of investors that purchased or otherwise acquired Zynex securities between March 13, 2023 and March 11, 2025 (the 'Class Period'). If you are an investor in Zynex and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than May 19, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. According to the complaint, on March 11, 2025, after the markets closed, Zynex reported their fourth quarter and full year financial results. The Company revealed a significant revenue 'shortfall' in the quarter 'due to slower than normal payments from certain payers.' The Company also revealed that Tricare, a health insurance program for the U.S. Military, 'has temporarily suspended payments as they review prior claims.' Following this news, the price of Zynex stock fell $3.59 per share, over 51%, to close at $3.41 per share on March 12, 2025. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (1) Zynex shipped products, including electrodes, in excess of need; (2) as a result of this practice, the Company inflated its revenue; (3) Zynex's practice of filing false claims drew scrutiny from insurers, including Tricare; and (4) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Jeffrey P. Campisi KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (212) 329-8571 Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612
Associated Press
26-03-2025
- Business
- Associated Press
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Zynex, Inc. (ZYXI) - Deadline is May 19, 2025
NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Zynex, Inc. ('Zynex' or the 'Company') (NASDAQ: ZYXI) on behalf of investors that purchased or otherwise acquired Zynex securities between March 13, 2023 and March 11, 2025 (the 'Class Period'). If you are an investor in Zynex and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than May 19, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. According to the complaint, on March 11, 2025, after the markets closed, Zynex reported their fourth quarter and full year financial results. The Company revealed a significant revenue 'shortfall' in the quarter 'due to slower than normal payments from certain payers.' The Company also revealed that Tricare, a health insurance program for the U.S. Military, 'has temporarily suspended payments as they review prior claims.' Following this news, the price of Zynex stock fell $3.59 per share, over 51%, to close at $3.41 per share on March 12, 2025. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (1) Zynex shipped products, including electrodes, in excess of need; (2) as a result of this practice, the Company inflated its revenue; (3) Zynex's practice of filing false claims drew scrutiny from insurers, including Tricare; and (4) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Jeffrey P. Campisi KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (212) 329-8571 Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612
